Quick Answer
Unicycive Therapeutics, Inc. reported Stockholders Equity of $30.20 million for fiscal year 2025.
Unicycive Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $30.20M | +306.4% |
| 2024 | $7.43M | +295.1% |
| 2023 | -$3.81M | -717.4% |
| 2022 | -$466.0K | -102.8% |
| 2021 | $16.48M | +717.1% |
| 2020 | -$2.67M | -202.1% |
| 2019 | -$884.0K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $37.48M | +234.6% | +128.1% |
| June 30, 2025 | $16.43M | +210.7% | +45.8% |
| March 31, 2025 | $11.27M | +146.1% | +51.7% |
| December 31, 2024 | $7.43M | +295.1% | +126.7% |
| September 30, 2024 | -$27.85M | -911.0% | -87.6% |
| June 30, 2024 | -$14.85M | +23.4% | +39.3% |
| March 31, 2024 | -$24.46M | -62.2% | -542.1% |
| December 31, 2023 | -$3.81M | -717.4% | -210.9% |
- Unicycive Therapeutics, Inc. showed an increase of +306.4% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2025 period, Unicycive Therapeutics, Inc.’s stockholders equity has grown by 3516.0% (from -$884.0 thousand to $30.20 million).
- The most recent figure is from Unicycive Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: